Omeros Corp (OMER): Net Income
-$3.35M
Year ended 2025-12-31
$124.83M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$3.35M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$156.81M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$117.81M | n/m | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | $47.42M | -75.6% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $194.24M | n/m | 2024-04-01, From 2021-01-01 |
| 2020-12-31 | -$138.06M | n/m | 2023-03-13, From 2020-01-01 |
| 2019-12-31 | -$84.49M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$126.76M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$53.48M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$66.75M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$75.10M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$73.67M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$39.80M | n/m | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | -$38.44M | n/m | 2015-03-16, From 2012-01-01 |
| 2011-12-31 | -$28.55M | n/m | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | -$29.25M | n/m | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | -$21.09M | n/a | 2012-03-15, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Omeros Corp (OMER) | 2025-12-31 | -$3.35M | n/m |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | -$75.27M | n/m |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | -$244.09M | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$171.30M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$68.92M | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$142.62M | n/m |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | -$223.12M | n/m |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | -$144.74M | n/m |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | -$166.31M | n/m |
Compare OMER, SION, PRTA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗